Experiences with
Jaypirca

4 public posts

Jaypirca?

Anybody have experience with jaypirca drug? Been told from pharmacist that is has lower risk for heart issues/atrial fibrillation than calquence but higher secondary cancer risks. Can anybody verify/share more?

Anybody have experience with jaypirca drug? Been told from pharmacist that is has lower risk for heart issues/atrial fibrillation than calquence but higher secondary cancer risks. Can anybody verify/share more?

8 months ago

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)

From MedPage Today's ASH 2024 coverage (registration needed) of the international BRUIN CLL-321 Phase III randomized trial with 238 patients, with my emphasis; https://www.medpagetoday.com/meetingcoverage/ashhematology/113337 [i]Pirtobrutinib (Jaypirca) delayed disease progression versus other available

From MedPage Today's ASH 2024 coverage (registration needed) of the international BRUIN CLL-321 Phase III randomized trial with 238 patients, with my emphasis; https://www.medpagetoday.com/meetingcoverage/ashhematology/113337 [i]Pirtobrutinib (Jaypirca) delayed disease progression versus other available

Partnerin CLL Support

1 month ago

Year in Review: Chronic Lymphocytic Leukemia - MedPage Today 12/10/2024

In a subgroup analysis of the BRUIN study -- which led to last year's approval of pirtobrutinib (Jaypirca) in CLL/SLL -- half of patients with Richter transformation responded to the oral non-covalent BTK inhibitor.

In a subgroup analysis of the BRUIN study -- which led to last year's approval of pirtobrutinib (Jaypirca) in CLL/SLL -- half of patients with Richter transformation responded to the oral non-covalent BTK inhibitor.

1 month ago

Want to take advantage of all our features? Just log in!

or

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

Pirtobrutinib (Jaypirca) /LOXO-305 (non-covalent) (First Non-covalent approved) https://cllsociety.org/2023/12/pirtobrutinib-is-the-first-reversible-btki-approved-in-cll-sll/ Works on patients with acquired resistance to available BTKis and venetoclax Starting at the 50 mg QD dose, Pirtobrutinib

Pirtobrutinib (Jaypirca) /LOXO-305 (non-covalent) (First Non-covalent approved) https://cllsociety.org/2023/12/pirtobrutinib-is-the-first-reversible-btki-approved-in-cll-sll/ Works on patients with acquired resistance to available BTKis and venetoclax Starting at the 50 mg QD dose, Pirtobrutinib

Partnerin CLL Support

5 years ago